Schrodinger, Inc. (SDGR)

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Ticker: SDGR
Exchange: Nasdaq
Sector: Healthcare
Industry: Health Information Services
Market cap: $2.24B
52-week range: $10.94 - $33.78

Valuation

Share price: $29.82 (close of Nov 6, 2026)
P/E (TTM): -38.23x
Price to book: 7.42x
Price to free cash flow: -19.17x
Enterprise value: $2.10B
Book value per share: $4.02

Price performance

Period	Change
1 day	+3.65%
5 days	+9.87%
1 month	+3.18%
3 months	+67.43%
6 months	+129.74%
Year to date	+66.78%
1 year	+59.89%
3 years	+7.81%
5 years	-47.94%
All time	+4.12%

Short interest

As of: Oct 15, 2026
Short % of float: 24.79%
Shares short: 10.40M
Days to cover: 3.35
Change since prior report: +2.67%
Source: FINRA consolidated short interest

Profitability and growth

Return on equity: -28.37%
Return on invested capital: -35.26%
Return on assets: -14.22%
Return on capital employed: -31.08%
Gross margin: 55.74%
Net margin: -40.36%
EBITDA margin: -62.87%
Revenue growth: 23.29%

Cash flow and balance sheet

Free cash flow yield (TTM): -5.22%
Current ratio: 2.75x
Net debt to EBITDA: 1.11x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
Revenue: $255.87M
Cost of revenue: $113.25M
Gross profit: $142.61M
EBITDA: -$160.87M
Net income: -$103.27M
Earnings per share: $-1.41
Research and development: $173.14M
Shares outstanding: 73.44M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$255.87M	$142.61M	-$103.27M	-$1.41
2024-12-31	$207.54M	$132.08M	-$187.12M	-$2.57
2023-12-31	$216.67M	$140.69M	$40.72M	$0.57
2022-12-31	$180.96M	$101.02M	-$149.19M	-$2.10
2021-12-31	$137.93M	$65.62M	-$100.39M	-$1.42
2020-12-31	$108.09M	$63.47M	-$24.46M	-$0.41
2019-12-31	$85.54M	$49.09M	-$24.57M	-$4.09
2018-12-31	$66.64M	$42.94M	-$28.43M	-
2017-12-31	$55.69M	$39.80M	-$17.39M	-

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	55.74%	-40.36%	-28.37%	-35.26%
2024-12-31	63.64%	-90.16%	-44.40%	-38.81%
2023-12-31	64.93%	18.79%	7.42%	-26.23%
2022-12-31	55.83%	-82.44%	-33.31%	-26.01%
2021-12-31	47.57%	-72.78%	-18.02%	-17.50%
2020-12-31	58.72%	-22.63%	-3.92%	-9.58%
2019-12-31	57.39%	-28.72%	-	-
2018-12-31	64.43%	-42.66%	-	-
2017-12-31	71.46%	-31.23%	-	-

Cash and debt by year

Period end	Cash
2025-12-31	$230.52M
2024-12-31	$147.33M
2023-12-31	$155.31M
2022-12-31	$90.47M
2021-12-31	$120.27M
2020-12-31	$202.30M
2019-12-31	$25.99M
2018-12-31	$77.72M
2017-12-31	$9.96M

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	$12.46M	$43.00M
2024-12-31	-$164.68M	$49.90M
2023-12-31	-$150.14M	$47.84M
2022-12-31	-$127.70M	$39.63M
2021-12-31	-$77.84M	$26.49M
2020-12-31	$14.22M	$10.54M
2019-12-31	-$27.89M	$2.19M
2018-12-31	-$28.97M	$1.31M
2017-12-31	-$19.01M	$888.00K

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-04	Sep 2026	-$0.66
2026-08-05	Jun 2026	-$0.60
2026-05-05	Mar 2026	-$0.56
2026-02-25	Dec 2025	-$0.13
2025-11-05	Sep 2025	-$0.75
2025-08-06	Jun 2025	-$0.83
2025-05-07	Mar 2025	-$0.71
2025-02-26	Dec 2024	-$0.35

Filings and sources

Company website: schrodinger.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Veeva Systems Inc (VEEV) · HealthEquity, Inc. (HQY) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV) · IDEXX Laboratories Inc (IDXX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades